Dipotassium phosphate
Identification
- Name
- Dipotassium phosphate
- Accession Number
- DB09414
- Description
Dipotassium phosphate (K2HPO4) is a highly water-soluble salt often used as a fertilizer and food additive as a source of phosphorus and potassium as well as a buffering agent.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Dipotassium phosphate (DB09414)
- Weight
- Average: 174.1759
Monoisotopic: 173.888658754 - Chemical Formula
- HK2O4P
- Synonyms
- Di-potassium hydrogen phosphate
- Dibasic potassium phosphate
- Dipotassium acid phosphate
- Dipotassium hydrogen monophosphate
- Dipotassium hydrogen orthophosphate
- Dipotassium hydrogen phosphate
- Dipotassium monophosphate
- Kali phosphoricum
- Phosphoric acid, dipotassium salt
- Phosphoric acid, potassium salt (1:2)
- Potassium phosphate dibasic
- Potassium phosphate, dibasic
- Potassium phosphate,dibasic
- Secondary potassium phosphate
- External IDs
- 231-834-5
- E-340(II)
- INS no.340(II)
- INS-340(II)
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
Dipotassium phosphate is used in imitation dairy creamers, dry powder beverages, mineral supplements, and starter cultures as an additive. It is used in non-dairy creamers to prevent coagulation. Dipotassium phosphate is also used to make buffer solutions and it is used in the production of trypticase soy agar which is used to make agar plates for culturing bacteria.
- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Phosphate is a major intracellular anion which participates in providing energy for metabolism of substances and contributes to important metabolic and enzymatic reactions in almost all organs and tissues. Phosphate exerts a modifying influence on calcium concentrations, a buffering effect on acid-base equilibrium, and has a major role in the renal excretion of hydrogen ions.
- Mechanism of action
Once phosphate gains access to the body fluids and tissues, it exerts little pharmacological effect. If the ion is introduced into the intestine, the absorbed phosphate is rapidly excreted. If large amounts are given by this route, much of it may escape absorption. Because this property leads to a cathartic action, phosphate salts are employed as mild laxatives.
- Absorption
Potassium salts are well absorbed from gastro intestinal tract. Net phosphorus absorption may occur in the small intestine in some species but is primarily a function of the colon in horses.
- Volume of distribution
Distribution is largely intracellular, but it is the intravascular concentration that is primarily responsible for toxicity.
- Protein binding
Phosphate is minimally protein bound, and highly concentrated in cells (intracellular concentrations are 100-fold higher than serum concentrations). Concentrations of phosphate in plasma are higher in children than in adults.
- Metabolism
Phosphate is a major intracellular anion which participates in providing energy for metabolism of substances and contributes to important metabolic and enzymatic reactions in almost all organs and tissues.
- Route of elimination
Potassium is excreted primarily by kidney.
- Half-life
In healthy children with phosphate overdose, half-life was 4.8 to 10.6 hours, and was prolonged to 17 hours in a child with renal insufficiency.
- Clearance
Phosphates are rapidly cleared by dialysis.
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
LD50 not available. Toxic effects in humans: Irritated skin, eye. Gastro intestinal irritation with nausea, vomiting, diarrhea, abdominal discomfort
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol Dipotassium phosphate may increase the hyperkalemic activities of Acebutolol. Aceclofenac Dipotassium phosphate may increase the hyperkalemic activities of Aceclofenac. Acemetacin Dipotassium phosphate may increase the hyperkalemic activities of Acemetacin. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Dipotassium phosphate. Acetylsalicylic acid Dipotassium phosphate may increase the hyperkalemic activities of Acetylsalicylic acid. Aclidinium The therapeutic efficacy of Dipotassium phosphate can be decreased when used in combination with Aclidinium. Alclofenac Dipotassium phosphate may increase the hyperkalemic activities of Alclofenac. Alfentanil The therapeutic efficacy of Dipotassium phosphate can be decreased when used in combination with Alfentanil. Aliskiren Dipotassium phosphate may increase the hyperkalemic activities of Aliskiren. Alloin The risk or severity of adverse effects can be increased when Dipotassium phosphate is combined with Alloin. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- No interactions found.
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Active Moieties
Name Kind UNII CAS InChI Key Potassium cation ionic 295O53K152 24203-36-9 NPYPAHLBTDXSSS-UHFFFAOYSA-N Phosphate ion ionic NK08V8K8HR 14265-44-2 NBIIXXVUZAFLBC-UHFFFAOYSA-K - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 2.5% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose Dipotassium phosphate (130.5 mg) + Alanine (520 mg) + Arginine (290 mg) + Dextrose, unspecified form (10 g) + Glycine (260 mg) + Histidine (120 mg) + Isoleucine (150 mg) + L-Lysine (145 mg) + Leucine (182.5 mg) + Magnesium chloride (25.5 mg) + Methionine (100 mg) + Phenylalanine (140 mg) + Proline (170 mg) + Serine (125 mg) + Sodium acetate (170 mg) + Sodium chloride (29.3 mg) + Threonine (105 mg) + Tryptophan (45 mg) + Tyrosine (10 mg) + Valine (145 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1996-12-31 2015-08-05 Canada 
2.5% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose Clinimix Dipotassium phosphate (130.5 mg) + Alanine (520 mg) + Arginine (260 mg) + Dextrose, unspecified form (10 g) + Glycine (520 mg) + Histidine (110 mg) + Isoleucine (120 mg) + L-Lysine hydrochloride (145 mg) + L-Leucine hydrochloride (155 mg) + Magnesium chloride (25.5 mg) + Methionine (145 mg) + Phenylalanine hydrochloride (155 mg) + Proline (105 mg) + Sodium acetate (170 mg) + Sodium chloride (29.3 mg) + Threonine (105 mg) + Tryptophan (45 mg) + Tyrosine (10 mg) + Valine (115 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1993-12-31 2015-08-05 Canada 2.5%travasol Amino Acid InJ.W.eleC.W.25%dex Dipotassium phosphate (130.5 mg) + Alanine (520 mg) + Arginine (290 mg) + Dextrose, unspecified form (25 g) + Glycine (260 mg) + Histidine (120 mg) + Isoleucine (150 mg) + L-Lysine (145 mg) + Leucine (182.5 mg) + Magnesium chloride (25.5 mg) + Methionine (100 mg) + Phenylalanine (140 mg) + Proline (170 mg) + Serine (125 mg) + Sodium acetate (170 mg) + Sodium chloride (29.3 mg) + Threonine (105 mg) + Tryptophan (45 mg) + Tyrosine (10 mg) + Valine (145 mg) Liquid Intravenous Clintec Nutrition Company 1996-07-30 1998-08-13 Canada 2.75% Travas. Amino Acid InJ.W.elecw.25%dex Dipotassium phosphate (261 mg) + Alanine (570 mg) + Arginine (316 mg) + Dextrose, unspecified form (25 g) + Glycine (283 mg) + Histidine (132 mg) + Isoleucine (165 mg) + L-Lysine (159.5 mg) + Leucine (201 mg) + Magnesium chloride (51 mg) + Methionine (110 mg) + Phenylalanine (154 mg) + Proline (187 mg) + Serine (137.5 mg) + Sodium acetate (215.5 mg) + Sodium chloride (112 mg) + Threonine (115.5 mg) + Tryptophan (49.5 mg) + Tyrosine (11 mg) + Valine (159.5 mg) Liquid Intravenous Clintec Nutrition Company 1996-07-30 1998-08-13 Canada 2.75% Travasol Amino Acid Injection With Electrolytes In 25% Dextrose Quickmix Dipotassium phosphate (261 mg) + Alanine (570 mg) + Arginine (285 mg) + Dextrose, unspecified form (25 g) + Glycine (570 mg) + Histidine (120.5 mg) + Isoleucine (131.5 mg) + L-Lysine hydrochloride (159 mg) + L-Leucine hydrochloride (170 mg) + Magnesium chloride (51 mg) + Methionine (159 mg) + Phenylalanine hydrochloride (170 mg) + Proline (115 mg) + Sodium acetate (215.5 mg) + Sodium chloride (112 mg) + Threonine (115 mg) + Tryptophan (49.5 mg) + Tyrosine (11 mg) + Valine (126 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1996-02-02 2007-08-02 Canada 2.75% Travasol Amino Acid Injection With Electrolytes In 5% Dextrose Quickmix Dipotassium phosphate (215.5 mg) + Alanine (570 mg) + Arginine (285 mg) + Dextrose, unspecified form (5 g) + Glycine (570 mg) + Histidine (120.5 mg) + Isoleucine (131.5 mg) + L-Lysine hydrochloride (159 mg) + L-Leucine hydrochloride (170 mg) + Magnesium chloride (51 mg) + Methionine (159 mg) + Phenylalanine hydrochloride (170 mg) + Proline (115 mg) + Sodium acetate (256 mg) + Sodium chloride (112 mg) + Threonine (115 mg) + Tryptophan (49.5 mg) + Tyrosine (11 mg) + Valine (126 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1993-12-31 2007-08-02 Canada 2.75%travasol Amino Acid InJ.W.eleC.W.5%dex. Dipotassium phosphate (261 mg) + Alanine (570 mg) + Arginine (316 mg) + Dextrose, unspecified form (5 g) + Glycine (283 mg) + Histidine (132 mg) + Isoleucine (165 mg) + L-Lysine (159.5 mg) + Leucine (201 mg) + Magnesium chloride (51 mg) + Methionine (110 mg) + Phenylalanine (154 mg) + Proline (187 mg) + Serine (137.5 mg) + Sodium acetate (215 mg) + Sodium chloride (112 mg) + Threonine (115.5 mg) + Tryptophan (49.5 mg) + Tyrosine (11 mg) + Valine (159.5 mg) Liquid Intravenous Clintec Nutrition Company 1996-12-31 1999-08-10 Canada 4.25% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose Dipotassium phosphate (261 mg) + Alanine (880 mg) + Arginine (489 mg) + Dextrose, unspecified form (10 g) + Glycine (438 mg) + Histidine (204 mg) + Isoleucine (255 mg) + L-Lysine hydrochloride (246.5 mg) + Leucine (310 mg) + Magnesium chloride (51 mg) + Methionine (170 mg) + Phenylalanine (238 mg) + Proline (289 mg) + Serine (212.5 mg) + Sodium acetate (297 mg) + Sodium chloride (77 mg) + Threonine (178.5 mg) + Tryptophan (76.5 mg) + Tyrosine (17 mg) + Valine (246.5 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1996-12-31 2015-08-05 Canada 4.25% Travasol Amino Acid Injection With Electrolytes In 20% Dextrose Dipotassium phosphate (261 mg) + Alanine (880 mg) + Arginine (489 mg) + Dextrose, unspecified form (20 g) + Glycine (438 mg) + Histidine (204 mg) + Isoleucine (255 mg) + L-Lysine hydrochloride (246.5 mg) + Leucine (310 mg) + Magnesium chloride (51 mg) + Methionine (170 mg) + Phenylalanine (238 mg) + Proline (289 mg) + Serine (212.5 mg) + Sodium acetate (297 mg) + Sodium chloride (77 mg) + Threonine (178.5 mg) + Tryptophan (76.5 mg) + Tyrosine (17 mg) + Valine (246.5 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1996-12-31 2007-08-02 Canada 4.25% Travasol Amino Acid Injection With Electrolytes In 20% Dextrose Quickmix Dipotassium phosphate (261 mg) + Alanine (880 mg) + Arginine (440 mg) + Dextrose, unspecified form (20 g) + Glycine (880 mg) + Histidine (186 mg) + Isoleucine (203 mg) + L-Lysine hydrochloride (246 mg) + L-Leucine hydrochloride (263 mg) + Magnesium chloride (51 mg) + Methionine (246 mg) + Phenylalanine hydrochloride (263 mg) + Proline (178 mg) + Sodium acetate (297 mg) + Sodium chloride (77 mg) + Threonine (178 mg) + Tryptophan (76 mg) + Tyrosine (17 mg) + Valine (195 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1995-12-31 2007-08-02 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Clinimix Dipotassium phosphate (2.61 g/1L) + Alanine (5.70 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + D-glucose monohydrate (75.00 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + L-Lysine (2.00 g/1L) + Leucine (2.01 g/1L) + Magnesium chloride hexahydrate (0.51 g/1L) + Methionine (1.10 g/1L) + Phenylalanine (1.54 g/1L) + Proline (1.87 g/1L) + Serine (1.38 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Threonine (1.16 g/1L) + Tryptophan (0.50 g/1L) + Tyrosine (0.11 g/1L) + Valine (1.60 g/1L) Solution Intravenous Baxter Healthcare Corporation 2017-10-25 2019-11-30 US 
Clinimix Dipotassium phosphate (5.22 g/2L) + Alanine (17.60 g/2L) + Arginine (9.78 g/2L) + Calcium chloride dihydrate (0.66 g/2L) + D-glucose monohydrate (300.00 g/2L) + Glycine (8.76 g/2L) + Histidine (4.08 g/2L) + Isoleucine (5.10 g/2L) + L-Lysine (4.93 g/2L) + Leucine (6.20 g/2L) + Magnesium chloride hexahydrate (1.02 g/2L) + Methionine (3.40 g/2L) + Phenylalanine (4.76 g/2L) + Proline (5.78 g/2L) + Serine (4.25 g/2L) + Sodium acetate trihydrate (5.94 g/2L) + Sodium chloride (1.54 g/2L) + Threonine (3.57 g/2L) + Tryptophan (1.53 g/2L) + Tyrosine (0.34 g/2L) + Valine (4.93 g/2L) Solution Intravenous Baxter Healthcare Corporation 2017-10-25 2019-11-30 US Clinimix Dipotassium phosphate (2.61 g/1L) + Alanine (5.70 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + D-glucose monohydrate (100.00 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + L-Lysine (2.00 g/1L) + Leucine (2.01 g/1L) + Magnesium chloride hexahydrate (0.51 g/1L) + Methionine (1.10 g/1L) + Phenylalanine (1.54 g/1L) + Proline (1.87 g/1L) + Serine (1.38 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Threonine (1.16 g/1L) + Tryptophan (0.50 g/1L) + Tyrosine (0.11 g/1L) + Valine (1.60 g/1L) Solution Intravenous Baxter Healthcare Corporation 2017-10-25 2019-11-30 US Potassium Phosphates Dipotassium phosphate (236 mg/1mL) + Monopotassium phosphate (224 mg/1mL) Injection, solution Intravenous American Regent 1989-11-19 2013-04-01 US Potassium Phosphates Dipotassium phosphate (236 mg/1mL) + Monopotassium phosphate (224 mg/1mL) Injection, solution Intravenous Fresenius Kabi USA, LLC 2000-08-08 2022-11-30 US Potassium Phosphates Dipotassium phosphate (236 mg/1mL) + Monopotassium phosphate (224 mg/1mL) Injection, solution Intravenous American Regent 1989-11-19 2012-12-01 US Potassium Phosphates Dipotassium phosphate (236 mg/1mL) + Monopotassium phosphate (224 mg/1mL) Injection, solution Intravenous American Regent 1989-11-19 2013-02-01 US Potassium Phosphates Dipotassium phosphate (236 mg/1mL) + Monopotassium phosphate (224 mg/1mL) Injection, solution, concentrate Intravenous Hospira, Inc. 2014-07-01 2014-07-01 US
Categories
- Drug Categories
- Acids
- Acids, Noncarboxylic
- Anions
- Buffers
- Cariostatic Agents
- Compounds used in a research, industrial, or household setting
- Dental Materials
- Electrolytes
- Ions
- Laboratory Chemicals
- Laxatives
- Osmotic Laxatives
- Phosphate salts
- Phosphoric Acids
- Phosphorus Acids
- Phosphorus Compounds
- Potassium Salt
- Protective Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as alkali metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkali metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Alkali metal oxoanionic compounds
- Sub Class
- Alkali metal phosphates
- Direct Parent
- Alkali metal phosphates
- Alternative Parents
- Inorganic salts / Inorganic oxides
- Substituents
- Alkali metal phosphate / Inorganic oxide / Inorganic salt
- Molecular Framework
- Not Available
- External Descriptors
- organic molecular entity (CHEBI:32031)
Chemical Identifiers
- UNII
- CI71S98N1Z
- CAS number
- 7758-11-4
- InChI Key
- ZPWVASYFFYYZEW-UHFFFAOYSA-L
- InChI
- InChI=1S/2K.H3O4P/c;;1-5(2,3)4/h;;(H3,1,2,3,4)/q2*+1;/p-2
- IUPAC Name
- dipotassium hydrogen phosphate
- SMILES
- [K+].[K+].OP([O-])([O-])=O
References
- General References
- External Links
- KEGG Compound
- C13197
- PubChem Compound
- 24450
- PubChem Substance
- 347827847
- ChemSpider
- 22858
- 55018
- ChEBI
- 131527
- ChEMBL
- CHEMBL1200459
- Wikipedia
- Dipotassium_phosphate
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2, 3 Terminated Treatment Hyposalivation 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intravenous Liquid Buccal Solution Intravenous 5 g/100ml Solution Intravenous 0.03 g/100ml Solution Intravenous 50 g/L Injection, solution Intravenous 4.02 g/l Injection, solution Intravenous 5.11 g/l Injection, solution Intravenous 6.21 g/l Injection, solution Intravenous 7.3 g/l Solution Intravenous Injection, solution Intravenous 0.91 g/1000ml Injection, solution Intravenous 0.91 g/L Injection, solution Intravenous 3.2 g/L Injection, solution Intravenous 3.2 g/1000ml Injection, solution Intravenous 3.38 g Injection, solution Intravenous 3.38 g/1000ml Injection Intravenous 1.394 g/20ml Solution Intravenous 2 g Spray Oral Aerosol, spray Oral 0.0026 g/50ml Liquid Intravesical Solution Intravenous 236 mg Solution Intravenous 5 % Solution Intravenous 55 g/L Solution Intravenous 5.5 g/100ml Powder Oral Injection, solution Intravenous 5 % Injection, solution, concentrate Intravenous Liquid Intravenous Aerosol Oral Spray Oral 5 mg Injection Intravenous Solution Intravenous 594 mg Powder, for solution Oral Solution Intravenous 87.1 mg/1ml - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US10632150 No 2019-04-19 2039-04-19 US
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -1 ChemAxon pKa (Strongest Acidic) 1.8 ChemAxon Physiological Charge -2 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 83.42 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 12.41 m3·mol-1 ChemAxon Polarizability 5.23 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Drug created on November 30, 2015 19:10 / Updated on June 12, 2020 16:52